×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AZN – astrazeneca plc - american depositary shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AZN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
08:17 am
azn
Novo Nordisk A/S (NVO) [Yahoo! Finance Canada]
Low
Report
Novo Nordisk A/S (NVO) [Yahoo! Finance Canada]
4/17
06:26 am
azn
Six FTSE 100 stock ideas for the second quarter, according to Barclays [Yahoo! Finance]
Low
Report
Six FTSE 100 stock ideas for the second quarter, according to Barclays [Yahoo! Finance]
4/17
02:13 am
azn
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? [Yahoo! Finance]
Low
Report
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? [Yahoo! Finance]
4/16
07:15 am
azn
Walmart boosts tech presence in India with Chennai office deal, document shows [Yahoo! Finance]
Low
Report
Walmart boosts tech presence in India with Chennai office deal, document shows [Yahoo! Finance]
4/15
02:50 pm
azn
European pharma companies issue demands to stay in EU ahead of expected US tariffs [Yahoo! Finance Canada]
Low
Report
European pharma companies issue demands to stay in EU ahead of expected US tariffs [Yahoo! Finance Canada]
4/15
02:39 pm
azn
European pharma companies issue demands to stay in EU ahead of expected US tariffs [Yahoo! Finance]
Low
Report
European pharma companies issue demands to stay in EU ahead of expected US tariffs [Yahoo! Finance]
4/15
02:38 pm
azn
European pharma companies issue demands to stay in EU ahead of expected US tariffs [Yahoo! Finance Canada]
Low
Report
European pharma companies issue demands to stay in EU ahead of expected US tariffs [Yahoo! Finance Canada]
4/15
01:26 pm
azn
AstraZeneca PLC (NASDAQ: AZN) is now covered by analysts at BNP Paribas. They set an "outperform" rating and a $75.00 price target on the stock.
Low
Report
AstraZeneca PLC (NASDAQ: AZN) is now covered by analysts at BNP Paribas. They set an "outperform" rating and a $75.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/11
01:40 pm
azn
Form 6-K ASTRAZENECA PLC For: Apr 11
Low
Report
Form 6-K ASTRAZENECA PLC For: Apr 11
4/4
06:43 am
azn
Form 6-K ASTRAZENECA PLC For: Apr 04
Medium
Report
Form 6-K ASTRAZENECA PLC For: Apr 04
4/4
06:06 am
azn
Form 6-K ASTRAZENECA PLC For: Apr 04
Medium
Report
Form 6-K ASTRAZENECA PLC For: Apr 04
4/1
12:30 pm
azn
Form 6-K ASTRAZENECA PLC For: Apr 01
Low
Report
Form 6-K ASTRAZENECA PLC For: Apr 01
3/31
07:16 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 31
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 31
3/31
07:11 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 31
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 31
3/21
08:32 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 21
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 21
3/17
07:30 am
azn
Form 6-K ASTRAZENECA PLC For: Mar 17
Low
Report
Form 6-K ASTRAZENECA PLC For: Mar 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
AstraZeneca's combo lung cancer treatment fails late-stage study main goal [Reuters (UK)]
8.3%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
TOP News Decliners
3/7
Amarin Stock Looks Like a Heart-Healthy Buy on the Dip [Yahoo! Finance News]
-4.1%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: